Collegium Pharmaceutical, Inc. (NASDAQ:COLL) insider Alison B. Fleming sold 4,601 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the transaction, the insider now directly owns 28,513 shares in the company, valued at approximately $491,849.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) opened at $17.21 on Thursday. Collegium Pharmaceutical, Inc. has a 1 year low of $7.37 and a 1 year high of $20.92.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The business had revenue of $11.95 million during the quarter, compared to analyst estimates of $5.31 million. During the same period in the prior year, the business posted ($1.13) earnings per share. The company’s revenue was up 2814.6% on a year-over-year basis. equities analysts expect that Collegium Pharmaceutical, Inc. will post -2.56 earnings per share for the current year.
Several brokerages recently issued reports on COLL. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Piper Jaffray Companies reiterated a “buy” rating and issued a $14.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. HC Wainwright began coverage on shares of Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a “buy” rating and a $21.00 target price for the company. Jefferies Group reiterated a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research report on Thursday, September 21st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $23.50.
A number of hedge funds and other institutional investors have recently bought and sold shares of COLL. American International Group Inc. boosted its position in Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the period. Voya Investment Management LLC purchased a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $125,000. Credit Suisse AG boosted its holdings in shares of Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after purchasing an additional 1,173 shares during the period. UBS Group AG boosted its holdings in shares of Collegium Pharmaceutical by 283.2% during the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 10,174 shares during the period. Finally, Tudor Investment Corp ET AL purchased a new stake in shares of Collegium Pharmaceutical during the first quarter worth about $151,000. Institutional investors and hedge funds own 79.98% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Insider Alison B. Fleming Sells 4,601 Shares” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2017/12/07/alison-b-fleming-sells-4601-shares-of-collegium-pharmaceutical-inc-coll-stock-updated-updated.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.